Perceive and Calculated CV Risk

Sponsor
Chinese University of Hong Kong (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05693857
Collaborator
Gormin Tan gtan (Other)
1,500
1
66
22.7

Study Details

Study Description

Brief Summary

Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making. Research has focused on refining the accuracy of these CV risk calculators for different populations, relatively little has been done to understand how patients perceive their own ASCVD risk. Accurate perception of a patient's risk by both the patient and the doctors is important because this is an important determinant of health-related behaviour. Patients often show optimistic bias when considering their own CV risk and consistently underestimate it.

We aim to determine patient perceived versus actual risk of ASCVD in a Chinese population. We aim to better understand the degree to which patients underestimate or overestimate their ASCVD risk and whether patients are better or worse at estimating their ASCVD risk relative to their peers of the same age and sex. Finally, we aim to evaluate patients willingness to follow guideline recommended CV prevention and specifically lipid-lowering therapy.

Condition or Disease Intervention/Treatment Phase
  • Other: Cardiovascular prevention guidelines

Detailed Description

Cardiovascular prevention guidelines use estimated 10-year atherosclerotic cardiovascular disease (ASCVD) risk to guide treatment decisions and engage patients in shared decision-making. Research has focused on refining the accuracy of these CV risk calculators for different populations, relatively little has been done to understand how patients perceive their own ASCVD risk. Accurate perception of a patient's risk by both the patient and the doctors is important because this is an important determinant of health-related behaviour. Patients often show optimistic bias when considering their own CV risk and consistently underestimate it.

We aim to determine patient perceived versus actual risk of ASCVD in a Chinese population. We aim to better understand the degree to which patients underestimate or overestimate their ASCVD risk and whether patients are better or worse at estimating their ASCVD risk relative to their peers of the same age and sex. Finally, we aim to evaluate patients willingness to follow guideline recommended CV prevention and specifically lipid-lowering therapy.

Study Design

Study Type:
Observational [Patient Registry]
Anticipated Enrollment :
1500 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Patient-Perceived Versus Actual Risk of Cardiovascular Disease and Willingness to Follow Recommendations for Cardiovascular Prevention
Anticipated Study Start Date :
Feb 11, 2023
Anticipated Primary Completion Date :
Feb 11, 2028
Anticipated Study Completion Date :
Aug 11, 2028

Outcome Measures

Primary Outcome Measures

  1. Evaluate correlation between patients' own estimates of their 10-year risk of heart disease or stroke with actual pooled-cohort-equation calculated risk estimates (using a validated CV risk calculation app). [12-months]

Secondary Outcome Measures

  1. Evaluate correlation between perceived and calculated 10-year CV risk in sub-groups based on age, sex, education level, known CV risks (e.g. smoking, diabetes, hyperlipidemia and hypertension [12-months]

  2. Evaluate patients' own estimates of 10-year CV risk relative to their peers using age- and sex-specific population risk percentiles. [12-months]

  3. Evaluate patients' willingness to follow recommendations for CV prevention based on their calculated 10-year CV risk profile (e.g. dietary, exercise, smoking and CV risk factor control) [12-months]

  4. Evaluate whether perceived or actual CVD risk is associated with current statin use or willingness to take statin. [12-months]

  5. Reasons for unwillingness to follow recommendations for CV preventions [12-months]

  6. Source of CV health information and advice [12-months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
40 Years to 90 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Aged 40 years and above

  2. Consent to complete questionnaire

  3. Lipid profile within 12 months

Exclusion Criteria:
  1. Known ASCVD defined as history of coronary heart disease (i.e. obstructive coronary disease, prior myocardial infarction, or prior coronary revascularization); cerebrovascular disease (i.e. stroke or transient ischemic attack); and peripheral arterial disease (i.e. obstructive peripheral disease, prior vascular amputation or prior revascularization)

  2. Other chronic illness with life-expectancy <12 months

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Chinese University of Hong Kong Shatin Hong Kong 999077

Sponsors and Collaborators

  • Chinese University of Hong Kong
  • Gormin Tan gtan

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Professor Bryan Ping Yen YAN, Professor, Chinese University of Hong Kong
ClinicalTrials.gov Identifier:
NCT05693857
Other Study ID Numbers:
  • 2022.573
First Posted:
Jan 23, 2023
Last Update Posted:
Jan 23, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Professor Bryan Ping Yen YAN, Professor, Chinese University of Hong Kong
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 23, 2023